Standard antibiotic sensitivity testing works by growing a patient's bacterial culture against a panel of drugs and watching which ones stop growth, a process that takes 24 to 48 hours in most hospital labs and longer in resource-constrained ones. During that wait, doctors have to guess, usually by prescribing a broad-spectrum antibiotic that may not be the right one and that itself contributes to resistance building up across the hospital. This product is a benchtop device that reads how bacteria respond electrically to a panel of antibiotics and returns an effective drug and dose in roughly thirty minutes to two hours, compressing a two-day guessing period into the length of a single hospital shift.

The buyer is hospital microbiology labs and ICU units, not individual physicians, because the economics only work where getting the antibiotic choice right fast actually changes outcomes, sepsis wards, ICUs, and surgical units with high rates of drug-resistant infection. The wedge is proving accuracy against the existing culture-based gold standard on a narrow panel of the antibiotics doctors misdose most often, then using that clinical data to expand both the drug panel and the regulatory approvals needed to sell more broadly.

This is a hardware and regulatory play, not a software one. Revenue comes from device placement plus per-test consumables in hospital labs, and the real product over time is less the device itself than the growing dataset of validated antibiotic-pathogen response pairs that each new approval and each new hospital deployment adds to.